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Trial DesignRandomized Evaluation of the Effects of
Anacetrapib through Lipid-modification
(REVEAL)—A large-scale, randomized,
placebo-controlled trial of the clinical effects
of anacetrapib among people with
established vascular disease: Trial design,
recruitment, and baseline characteristics
REVEAL Collaborative Group1, L. Bowman, F. Chen, E. Sammons, J.C. Hopewell, K. Wallendszus, W. Stevens, E. Valdes-
Marquez, S. Wiviott, C.P. Cannon, E. Braunwald, R. Collins, M.J. Landray (Writing Committtee) Oxford, United KingdomBackground Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin–
based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol
by around 25% to 40% and more than doubles high-density lipoprotein (HDL) cholesterol. However, it is not known if these
apparently favorable lipid changes translate into reductions in cardiovascular events.
Methods The REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy
and safety of adding anacetrapib to effective LDL-lowering treatment with atorvastatin for an average of at least 4 years among
patients with preexisting atherosclerotic vascular disease. The primary assessment is an intention-to-treat comparison among all
randomized participants of the effects of allocation to anacetrapib on major coronary events (defined as the occurrence of
coronary death, myocardial infarction, or coronary revascularization).
Results Between August 2011 and October 2013, 30,449 individuals in Europe, North America, and China were
randomized to receive anacetrapib 100 mg daily or matching placebo. Mean (SD) age was 67 (8) years, 84% were male,
88% had a history of coronary heart disease, 22% had cerebrovascular disease, and 37% had diabetes mellitus. At the
randomization visit (after at least 8 weeks on a protocol-defined atorvastatin regimen), mean plasma LDL cholesterol was 61
(15) mg/dL and HDL cholesterol was 40 (10) mg/dL.
Interpretation The REVEAL trial will provide a robust evaluation of the clinical efficacy and safety of adding
anacetrapib to an effective statin regimen. Results are anticipated in 2017. (Am Heart J 2017;187:182-90.)From the REVEALCentral CoordinatingOffice, Clinical Trial Service Unit and Epidemiological
Studies Unit, Nuffield Department of PopulationHealth, University ofOxford, United Kingdom.
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Large-scale randomized trials have shown that lowering
low-density lipoprotein (LDL) cholesterol concentration
by about 40 mg/dL (1 mmol/L) for 4 to 5 years reduces the
risk of coronary events (including myocardial infarction
[MI], coronary death, and revascularization procedures)
and stroke by about one-fifth,1 and that lowering LDL
cholesterol more (either with more effective statin
regimens or with the addition of ezetimibe) produces
further reductions in risk.2,3 Nevertheless, among individ-
uals who already have occlusive vascular disease, the risk
of cardiovascular events remains high.2,3
Although higher high-density lipoprotein (HDL) cholester-
ol concentration is associated with lower risk of coronary
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little evidence that treatments that raise HDL cholesterol
reduce the risk of vascular events. Trials using fibrates
(which raise HDL cholesterol by about 5%-10%) have
produced mixed results,6 whereas adding niacin (which
increases HDL cholesterol by 14%-20%) to a statin had no
effect on the risk of cardiovascular events butwas associated
with significant hazards (including serious adverse events
[SAEs] related to the gastrointestinal and musculoskeletal
systems, skin, diabetes, infection, and bleeding).7,8
Cholesteryl ester transfer protein (CETP) facilitates
exchange of cholesteryl esters and triglycerides between
HDL particles and atherogenic apolipoprotein B–containing
particles in the plasma. Genetic variants that lead to
lower CETP activity are associated with higher HDL
cholesterol levels and lower risk of coronary heart
disease9,10 (by contrast with other genetic variants that
impact HDL cholesterol levels).11 Pharmacological CETP
inhibition produces increases in HDL cholesterol and
apolipoprotein A1, along with reductions in LDL
cholesterol and apolipoprotein B.12 The magnitude of
these effects varies between different CETP inhibitors.
Torcetrapibwas the first CETP inhibitor to be studied in a
large-scale outcome trial. However, the ILLUMINATE
trial in 15,000 patients with preexisting cardiovascular
disease was stopped prematurely in 2007 because of an
excess risk of death among patients allocated to receive
torcetrapib.13 Torcetrapib was found to increase systolic
blood pressure by about 5 mm Hg as well as causing
increases in blood sodium, bicarbonate, and aldosterone
concentrations.13-15
Cardiovascular outcome trials with 2 other CETP
inhibitors were also terminated early because of a lack
of efficacy. In 2012, the Dal-OUTCOMES trial of
dalcetrapib in 16,000 patients with a recent acute
coronary syndrome was stopped prematurely because
of a lack of clinically meaningful reductions in cardiovas-
cular events but with no significant safety concerns.16
Dalcetrapib has only modest effects on blood lipids,
increasing HDL cholesterol by about 30% with no effect
on LDL cholesterol, and also increasing systolic blood
pressure by 0.6 mm Hg in Dal-OUTCOMES. In 2015, the
ACCELERATE trial of evacetrapib, which doubles HDL
cholesterol and lowers LDL cholesterol by about one
quarter,17,18 was stopped early because of insufficient
evidence of efficacy.19,20 There was an increased risk of
investigator-reported hypertension and a 1 mm Hg
increase in systolic blood pressure.
Anacetrapib is an orally active CETP inhibitor thatwaswell
tolerated in early-phase studies. In the placebo-controlled
DEFINE trial among 1,600 patients followed up for
18 months, anacetrapib 100 mg daily produced substantial
increases in HDL cholesterol and apolipoprotein A1 (138%
and 45%, respectively) and reductions in LDL cholesterol,
apolipoprotein B, and lipoprotein(a) (40%, 21%, and 36%,
respectively).21 However, subsequent investigations suggestthat the reduction in LDL cholesterol may be somewhat
smaller (around 25%) if measured by β-quantification rather
than direct methods.22 There have been no discernible
effects on resting or ambulatory blood pressure or on plasma
aldosterone concentrations.23
The REVEAL trial was designed to assess the clinical
efficacy and safety of anacetrapib 100 mg once daily
among patients with preexisting atherosclerotic vascular
disease who are also receiving effective LDL-lowering
therapy using atorvastatin. In this article, we present the
REVEAL trial design, prerandomization recruitment and




The REVEAL trial aimed to randomize at least 30,000
participants 50 years or older with preexisting atheroscle-
rotic vascular disease between anacetrapib 100 mgdaily and
matching placebo for a median of at least 4 years
(Supplementary Figure 1). All participants were to receive
effective LDL-lowering treatment using atorvastatin. The
primary outcome for the assessment of efficacy is major
coronary event, which is defined as coronary death, MI, or
coronary revascularization (Figure 1).
Study organization
The study was designed by the independent investiga-
tors at the Clinical Trial Service Unit at the University of
Oxford (the regulatory trial sponsor) in collaboration with
the TIMI Study Group based at Brigham and Women's
Hospital, Boston, and Merck & Co, Inc (Merck), which
manufactures anacetrapib and provides funding for the
study. The independent Steering Committee is responsible
for drafting the main reports from the study. Although
Merck has the opportunity to comment on drafts of
manuscripts, it otherwise has no role in the analysis of the
data presented, the preparation and approval of this
manuscript, or the decision to submit it for publication.
The study protocol (see Supplementary Material) was
approved by the relevant institutional review board and
drug regulatory authority for each participating center.
Eligibility
The REVEAL trial aimed to enroll a broad range of
participants at high risk for future cardiovascular events (see
Figure 2). Men and women older than 50 years were
considered eligible if they met at least one of the inclusion
criteria (history of MI, cerebrovascular atherosclerotic
disease, peripheral arterial disease, or diabetes mellitus
withother evidenceof symptomatic coronary heart disease),
had none of the exclusion criteria, and if their own doctor
did not consider there to be a definite contraindication to
either anacetrapib or atorvastatin (the protocol-specified





Major atherosclerotic event: Coronary death, myocardial infarction or presumed ischaemic
stroke (the key secondary outcome)
Presumed ischaemic stroke: (i.e. not known to be haemorrhagic)
Major vascular event: Coronary death, myocardial infarction, coronary revascularization
procedure or presumed ischaemic stroke
* Coronary death includes deaths due to myocardial infarction, other consequences of coronary atherosclerosis (such as
ischaemic heart failure) and sudden cardiac death. Definitions of each of these outcomes are provided in the
Supplementary Material.  
†
 In addition, each of the individual components of the primary outcome will be tested separately. Further details of all
analyses are provided in the Data Analysis Plan (see Supplementary Material).
Primary and secondary outcomes.
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Extensive prescreening efforts were made to identify
large numbers of potential participants at each recruiting
site. Potentially eligible patients were identified from
clinical records (including electronic health care records)
and, in many places, were contacted to seek their
provisional agreement to attend a screening visit. The
exact methods varied by center and by country, and in all
cases were subject to appropriate institutional review
board approval and compliance with data privacy
regulations. Potential participants were given information
about the study and invited to attend a screening visit.
At the screening visit, relevant medical history, current
medication, and other factors pertinent to eligibility were
recorded directly on to the screening visit form on the study
IT system (which was designed to ensure that complete
informationwas obtained and to prompt actions in linewith
the protocol). Potentially eligible individuals had the study
explained to them by the clinic staff and were asked to
provide written informed consent. In addition, they were
asked to indicate on the consent form which, if any, of the
samples of plasma, serum, cells, or urine could be stored long
term for future unspecified research analyses. Blood
pressure was measured and a non–fasting blood sample
was taken for immediate measurement of total cholesterol,
alanine transaminase (ALT), creatine kinase (CK), and
creatinine using a Reflotron Plus (Roche Diagnostics
International, Rotkreuz, Switzerland) dry chemistry analyzer.
These results were recorded directly on the study clinic IT
system, which provided an assessment of eligibility and
determined the atorvastatin dose to be used for that
individual (see below). At the end of the screening visit,
eligible participants were issued with a 12-week supply of
active atorvastatin (at an appropriate dose) and placebo
anacetrapib, with 1 tablet of each to be taken daily. All otherlipid-modifying treatments were stopped. An appointment
was made for a randomization visit in 8 to 12 weeks.
The prerandomization, single-blind, run-in phase was
intended to help identify and exclude before randomization
those individuals who would be unlikely to comply with
long-term study treatment and follow-up. During run-in, the
local investigator (and, where appropriate, each individual's
primary care physician or hospital specialist) was given a
description of their patient's medical history, previous
lipid-modifying treatment and screening visit total cholester-
ol result, and advised of the atorvastatin dose that would be
provided during the trial. The doctor was asked to indicate
whether, in their view, their patient was unsuitable for entry
into the randomized phase of the study (for whatever
reason). The run-in period also provided screened partici-
pants with the opportunity to consider whether they
remainedwilling to take part in the randomized comparison,
take study medication, and attend follow-up visits for at least
4 to 5 years.
Determination of atorvastatin dose
All participants who entered the run-in phase were issued
with an atorvastatin regimen that was intended to reduce
their LDL cholesterol to less than 77 mg/dL (2 mmol/L) and
whichwas at least as intensive as their current LDL-lowering
treatment (see Supplementary Material). At the screening
visit, a computerized algorithm used the dry chemistry total
cholesterol measurement and the type and dose of their
current (prestudy) LDL-lowering therapy (statin and/or
ezetimibe) to determine eligibility and the minimum dose
of study atorvastatin (either 10 or 20 mg in China, 20 or
80 mg in other countries) likely to be required to lower total
cholesterol to less than 135 mg/dL (3.5 mmol/L). Individuals
were excluded if they were already receiving LDL-lowering
treatment that was more intensive than the maximum
Figure 2
ALT – alanine transaminase; CK – creatine kinase; LDL – low density lipoprotein; ULN – upper limit of normal
* Individuals with a history of acute hepatitis are eligible provided this ALT limit is not exceeded
†
 Individuals who were taking such drugs temporarily could be re-screened when they discontinue them, if considered
appropriate. 
‡
 atorvastatin 20 mg daily in China or 80 mg daily in other countries
§
 The randomization visit occurred after an 8-12 weeks run-in period during which participants received study atorvastatin
plus placebo anacetrapib 
Tablet counts were not required
Inclusion criteria
Patients must be aged at least 50 at the time of initial invitation, and at least one of the following inclusion criteria
must be satisfied: 
History of myocardial infarction (MI);
Cerebrovascular atherosclerotic disease (history of presumed ischaemic stroke or carotid revascularization);
Peripheral arterial disease (history of non-coronary revascularization, including aortic aneurysm repair or graft);
or 
Diabetes mellitus with other evidence of symptomatic coronary heart disease (treatment or hospitalization for
angina, or a history of coronary revascularization or acute coronary syndrome).
Exclusion criteria
Acute MI, acute coronary syndrome or stroke within 4 weeks prior to Screening Visit or during run-in;
Planned coronary revascularization procedure within the next 6 months;
Definite history of chronic liver disease, or abnormal liver function (i.e. ALT >2x ULN)*;
Severe renal insufficiency (i.e. creatinine >2.3 mg/dL [200 µmol/L ], dialysis or functioning renal transplant);
Evidence of active inflammatory muscle disease, or CK >3x ULN;
Previous significant adverse reaction to a statin or anacetrapib;
Current treatment with any of the following lipid-lowering treatments:
(i) a regimen considered to produce substantially greater LDL cholesterol reduction than atorvastatin
20 mg daily for individuals in China or 80 mg daily for those in other countries;
(ii) fibric acid derivative (“fibrate”, including gemfibrozil); or
(iii) niacin (nicotinic acid) at doses above 100 mg daily;
Concurrent treatment with a medication that is contraindicated with anacetrapib or atorvastatin†; 
Known to be poorly compliant with clinic visits or prescribed medication;
Medical history that might limit the individual’s ability to take trial treatments for the duration of the study;
Women of child-bearing potential (unless using adequate contraception); or
Current participation in a clinical trial with an unlicensed drug or device.
Individuals were also to be excluded at the Screening visit if it was considered unlikely that they would achieve total
cholesterol <135 mg/dL (3.5 mmol/L) on the highest atorvastatin dose available in their region‡.
Additional exclusion criteria at the randomization visit
§
In addition to the above, individuals must be excluded at the randomization visit if any of the following are true:
Total cholesterol above 155 mg/dL (4 mmol/L) 
Non-compliant with run-in treatment (<90% scheduled run-in medication taken)
Individual is no longer willing to be randomized into the 4-5 year trial
The individual’s doctor is of the view that their patient should not be randomized
Inclusion and exclusion criteria for entry into the REVEAL trial.
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they would achieve the target total cholesterol on that dose
of atorvastatin.
Randomization visit
At the randomization visit, eligibility was rechecked and
information on SAEs and any other significant problems
during the run-in period were recorded. Nonstudy medica-
tion, compliance with run-in treatment, and consent
information were checked. Information about smoking
history and alcohol intake was sought and an assessment
of quality of life was made using the EQ5D questionnaire.
Blood pressure (measured once with patient sitting usingOmron BP760 (Omron Healthcare UK, Milton Keynes, UK)
or equivalent local model), height, weight, and hip, waist,
and neck circumference were measured. All details were
recorded directly on the Randomization Form on the clinic
IT system. A blood sample was taken for immediate dry
chemistry measurement of total cholesterol, ALT, and CK.
Individuals could only remain eligible if total cholesterol was
≤155 mg/dL (4 mmol/L), ALT ≤2× upper limit of normal,
and CK ≤3× upper limit of normal. Additional non–fasting
blood samples and a urine sample were taken for central
laboratory assays of lipid profile, glycosylated hemoglobin,
plasma creatinine, and urinary albumin/creatinine ratio (see
Supplementary Material). Samples of genetic material,
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future analysis, subject to appropriate consents.
Eligible and consenting individuals were allocated anace-
trapib or placebo using aminimized randomization program
embedded within the clinic IT system that helps maximize
balance between the treatment groups with respect to
prognostically important variables (see Supplementary
Material).24 Randomized participants were issued with a
7-month supply of study treatment consisting of (a)
anacetrapib 100 mg or matching placebo, and (b) active
atorvastatin (at the same dose issued at the screening visit).
An appointment for the first postrandomization follow-up
visit was made and the participant's doctor(s) was notified
that his/her patient had been randomized.
Post‐randomization follow-up
After randomization, it is intended that all participants
remain on study treatment and that follow-up information
is collected for the full duration of the study. Clinic
follow-up visits are scheduled at 2 and 6 months initially
(with an additional visit at 4 months in China, at the
request of the Chinese Food and Drug Administration),
and then 6 monthly until the end of the study. Additional
“early recall” visits are arranged for any participants who
require review outside their planned visit schedule.
Details of the follow-up visit assessments are provided
in the Supplementary Material. Wherever possible,
extended follow-up (off study treatment) of all surviving
randomized participants will continue for at least 2 years
beyond the final study visit to provide information on the
longer-term safety and efficacy of anacetrapib.
Adverse event recording and adjudication of potential
study outcomes
At each follow-up visit, study staff seek details of all SAEs
(including study outcomes and reasons for hospitalization),
any non-serious adverse events attributed to or resulting in
discontinuation of study treatment, and any symptoms of
muscle pain or weakness or suggestive of hepatitis (loss of
appetite, nausea, jaundice, lethargy, ormalaise). At the request
of the US Food and Drug Administration, information on all
other non-serious adverse events is sought for participants in
North America. Potential study outcomes are adjudicated by
clinicians based at or overseen by the Central Coordinating
Office, blind to study treatment allocationorblood lipid values
and using standard definitions (see Supplementary Material).
Statistical considerations
Sample size and predicted number of events.
Based on a major coronary event rate of 1.8% per annum
and median follow-up of 4 years, a trial of 30,000
participants would have 88% power at 2-tailed P b .01
to detect a 15% relative risk reduction (see Supplemen-
tary Material). Follow-up of all randomized participants is
planned to continue for a median of at least 4 years, and
until at least 1900 participants have had an unrefutedmajor coronary event (primary end point) plus at least
950 participants have had a coronary death or MI.
Data analysis plan. All participants randomized to
anacetrapib will be compared with all participants
randomized to placebo, regardless of whether a partic-
ipant received all, some or none of the allocated
treatment (ie, intention-to-treat analyses). For each
outcome, survival analytic methods will be used to
evaluate the time to the first event during the entire study
period. The log-rank method will be used to estimate the
average event rate ratio comparing all those allocated active
anacetrapib with all those allocated placebo. A 2-tailed P
value b.05 will be considered statistically significant. Further
details (including the approach to control for multiplicity)
are provided in the protocol, Data Analysis Plan, and other
online Supplementary Material, which were finalized by the
trial Steering Committee blind to any information on the
effect of study treatment on study outcomes.
Roleof the independentDataMonitoringCommittee.
An independent Data Monitoring Committee (DMC) is
responsible for reviewing interim unblinded analyses of the
effect of randomized treatment allocation on all SAEs and
other study outcomes. The DMC is to advise the Steering
Committee if, in their view, any modification to the protocol
is required. Such assessments are carried out at a frequency
relevant to the stage of the study (typically at 6-12 monthly
intervals with a Chairman's review every 3-6 months).
Further details, including guidelines for once only consider-
ation of stopping for benefit or futility at 3 years' median
follow-up, are provided in the DMC Charter (see Supplemen-
tary Material).Results
Screening and run-in
A total of 49,787 patients attended a screening visit (see
Figure 3): 29,318 in Europe, 8,249 in North America, and
12,220 in China (see Supplementary Table I). Data from
one additional site in the United States have been
excluded from this report because of evidence of
significant breaches of Good Clinical Practice and the
study protocol (see Supplementary Material).
Of the 49,787 people screened, 11,541 (23.2%) were
excluded at the screening visit, 4,820 (9.7%) withdrew
during the run-in period, and 2,977 (6.0%) were not
eligible at the randomization visit. Of those screened,
1,406 (2.8%) did not meet any of the inclusion criteria,
1,441 (2.9%) were excluded on the basis of medical
history, 1,392 (2.8%) were excluded because of concerns
about long-term compliance with study medication and/
or attendance at clinic visits, and 963 (1.9%) did not give
consent (see Supplementary Table II). A total of 1,550
(3.1%) were excluded on the basis of medication history,
with the chief reasons being a participant report of
previous adverse reaction to a statin (735 [1.5%]) and the
use of an LDL-lowering treatment regimen (statin and/or
Figure 3
Note: Participants may have more than 1 reason for not progressing from one stage of the process to the next.
Trial profile — flow of participants through the REVEAL trial.
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the maximum dose of study atorvastatin (621 [1.2%]). A
total of 5,437 (10.9%) individuals were excluded on the
basis of their blood assay results, with 4,814 (9.7%) being
due to a total cholesterol result that, together with
knowledge of their current LDL-lowering treatment, gave
a predicted total cholesterol result that was unlikely to be
less than 135 mg/dL (3.5 mmol/L) on the maximum dose
of study atorvastatin for their region. Overall, of the
11,541 individuals who were excluded at the screening
visit, 5,435 (47%) were excluded either because their
current LDL-lowering treatment was considered to be
more potent than the maximal dose of study atorvastatin
available or because it was considered unlikely that their
total cholesterol would be less than 135 mg/dL
(3.5 mmol/L) on study atorvastatin.
Of the 38,246 individuals who entered the run-in phase,
4,820 (12.6%) withdrew before attending a randomiza-
tion visit (see Supplementary Table III). A total of 52(0.1%) died of causes unrelated to study medication, 265
(0.7%) withdrew because of a nonfatal SAE (of which 4
were believed to be caused by the study atorvastatin), and
1,621 (4.2%) withdrew because of a non-serious adverse
event (with musculoskeletal and gastrointestinal disor-
ders being the most common). A total of 2887 (7.5%) had
other reasons for withdrawing from run-in, principally
concerns about or difficulty taking tablets, difficulty in
traveling or attending clinic, or advice from their doctor.
Of the 33,426 individuals who attended a randomiza-
tion visit, 2,977 (8.9%) were not eligible for randomiza-
tion (see Supplementary Table IV). Of these, 6 (0.0%) no
longer met the inclusion criteria, 1,063 (3.2%) were
excluded on the basis of medical history (including 1
reported serious adverse reaction to study atorvastatin),
448 (1.3%) were on a contraindicated medication or
poorly compliant with the run-in treatment (atorvastatin
plus placebo anacetrapib), there were concerns about
long-term compliance with study medication in 580
Table. Baseline characteristics of randomized participants.
Europe North America China Total
Number randomized 15,738 6082 8629 30,449
Age (y) 68 ± 8 67 ± 8 64 ± 8 67 ± 8
Male 13,652 (87%) 5058 (83%) 6824 (79%) 25,534 (84%)
Atorvastatin dose⁎
Low 7969 (51%) 2621 (43%) 4519 (52%) 15,109 (50%)
High 7769 (49%) 3461 (57%) 4110 (48%) 15,340 (50%)
Prior disease†
Coronary heart disease 13,306 (85%) 5697 (94%) 7676 (89%) 26,679 (88%)
Cerebrovascular disease 3348 (21%) 1131 (19%) 2302 (27%) 6781 (22%)
Peripheral arterial disease 1645 (10%) 714 (12%) 76 (1%) 2435 (8%)
Diabetes 4678 (30%) 2682 (44%) 3960 (46%) 11,320 (37%)
Heart failure 785 (5%) 343 (6%) 643 (7%) 1771 (6%)
b12 mo since qualifying event 2420 (15%) 1060 (17%) 1933 (22%) 5413 (18%)
Physical measurements
Systolic blood pressure (mm Hg) 131 ± 18 129 ± 18 133 ± 20 131 ± 19
Diastolic blood pressure (mm Hg) 78 ± 11 76 ± 11 79 ± 12 78 ± 11
Body mass index (kg/m2) 29 ± 5 31 ± 6 26 ± 3 29 ± 5
Waist-hip ratio‡ 0.97 ± 0.08 0.98 ± 0.08 0.92 ± 0.05 0.96 ± 0.07
Medication
ACE inhibitor or ARB 11,879 (75%) 4400 (72%) 4050 (47%) 20,329 (67%)
Antiplatelet therapy 14,261 (91%) 5654 (93%) 7992 (93%) 27,907 (92%)
Diuretic 3965 (25%) 1831 (30%) 728 (8%) 6524 (21%)
Calcium-channel blocker 4045 (26%) 1461 (24%) 2679 (31%) 8185 (27%)
β-Blocker 10,897 (69%) 4665 (77%) 5112 (59%) 20,674 (68%)
Biochemistry
Total cholesterol (mg/dL) 136 ± 21 126 ± 21 129 ± 22 132 ± 21
LDL cholesterol (mg/dL) 63 ± 15 58 ± 14 59 ± 15 61 ± 15
HDL cholesterol (mg/dL) 43 ± 10 37 ± 9 37 ± 8 40 ± 10
Non–HDL cholesterol (mg/dL) 93 ± 19 89 ± 19 91 ± 20 92 ± 19
Triglycerides (mg/dL) 119 (87-167) 122 (87-172) 135 (97-192) 124 (89-174)
Apolipoprotein A1 (mg/dL) 124 ± 19 115 ± 18 116 ± 15 120 ± 18
Apolipoprotein B (mg/dL) 67 ± 13 64 ± 12 61 ± 12 65 ± 13
Lipoprotein(a) (nmol/L) 22 (8-104) 26 (9-111) 22 (10-61) 23 (9-88)
Glomerular filtration rate (ml/min per 1.73 m2)‡ 81 ± 17 80 ± 18 90 ± 15 83 ± 17
Urinary albumin/creatinine ratio (mg/g) 8 (4-21) 8 (4-29) 8 (4-23) 8 (4-23)
Results are count (%), mean ± SD, or median (interquartile range).
Abbreviations: ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
⁎ Low-dose atorvastatin = 10 mg in China and 20 mg elsewhere; high-dose atorvastatin = 20 mg in China and 80 mg elsewhere.
† Participants may have a history of more than 1 of these conditions.
‡ Estimated using the CKD EPI formula.30
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regular study visits. A total of 1,606 (4.8%) individuals
were excluded on the basis of the blood results, including
1,097 (3.3%) with a total cholesterol result greater than
155 mg/dL (4.0 mmol/L).
Baseline characteristics of randomized participants
Between August 2011 and October 2013, 30,449
people (61.2% of those screened) were randomized:
15,738 from Europe, 6,082 from North America, and
8,629 from China (see Table and Supplementary Table V).
Mean (SD) age was 67 (8) years and 25,534 (84%) were
men. Overall, 26,679 (88%) had a history of coronary
heart disease, 6,781 (22%) had a history of cerebrovascu-
lar disease, 2,435 (8%) had a history of peripheral arterial
disease, and 11,320 (37%) had diabetes mellitus. The
mean total cholesterol was 132 (21) mg/dL, LDLcholesterol was 61 (15) mg/dL (4,297 [14%] had LDL
cholesterol≥77 mg/dL [2.0 mmol/L]; see Supplementary
Table VI), HDL cholesterol was 40 (10) mg/dL, and
median (inter-quartile range) plasma triglycerides were
124 (89-174) mg/dL.
Emerging information on adherence to study treatment
and event rate
At a median of 3 years of follow-up, the overall
adherence to randomized study treatment was 88% and
the observed blinded major coronary event rate was 2.7%
per year. In November 2015, the DMC considered the
guidelines for premature stopping (see Supplementary
Material) and recommended that the study continue as
planned. At a median follow-up of 4 years, REVEAL is
anticipated to have 98% power at 2-tailed P b .01 to detect
a 15% relative risk reduction in the primary outcome.
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The REVEAL trial seeks to assess the efficacy and safety
of adding anacetrapib 100 mg daily to effective
LDL-lowering treatment among 30,449 patients at high
risk for cardiovascular events. The prerandomization
screening and run-in phase successfully ensured that all
participants were receiving appropriate doses of atorva-
statin and the resulting mean baseline LDL cholesterol
concentration (61 mg/dL) is in line with that anticipated
in the study protocol (67 mg/dL).
Extended follow-up of a subset of DEFINE participants
showed that anacetrapib has a long terminal half-life such that
low levels of anacetrapib (about 8% of apparent steady-state
on-treatment trough exposures and 2% of apparent
steady-state peak concentrations) were detected in blood
2.5 to 4 years after cessation of therapy.25 Preliminary data
demonstrate that anacetrapib accumulates in adipose tissue
and appears to have a prolonged elimination phase from fat.26
Although drug concentrations appear to reach a plateau in
plasma by 4 weeks of dosing, adipose tissue concentration of
anacetrapib continues to increase for at least 16 weeks of
dosing. Up to 1 year after cessation of therapy, only minimal
declines in adipose levels of anacetrapib are seen despite a
substantial decline in plasma concentration. Preclinical
toxicology and exploratory studies performed to date have
not indicated any deleterious effects of anacetrapib on
adipose tissue structure or function. To explore this issue
further, serial adipose tissue biopsies and plasma samples
are being taken from several hundred REVEAL participants
after at least 18 months of anacetrapib dosing. The planned
extended follow-up of all surviving randomized partici-
pants (off treatment) will also provide valuable information
on the longer-term effects of the study treatment (as has
been done for a number of previous lipid treatment
trials).27-29
By contrast with the ACCELERATE trial of evacetra-
pib,18,20 the REVEAL trial of anacetrapib (which has
similar effects on lipids) has recruited more participants
(30,449 vs 12,092), included a lower proportion with
recent acute coronary syndrome (15% vs 31%), has
longer duration of follow-up (about 4 years vs around
2.5 years), and involves more primary cardiovascular
events (anticipated over 3,000 vs about 1,500). Thus, the
REVEAL trial will provide a robust assessment of the
efficacy and safety of anacetrapib among individuals at
high risk for cardiovascular events who are receiving
effective LDL-lowering treatment. The main study results
are anticipated later in 2017.The REVEAL Collaborative Group
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